AR126238A1 - HER2 MUTATION INHIBITORS - Google Patents
HER2 MUTATION INHIBITORSInfo
- Publication number
- AR126238A1 AR126238A1 ARP220101664A ARP220101664A AR126238A1 AR 126238 A1 AR126238 A1 AR 126238A1 AR P220101664 A ARP220101664 A AR P220101664A AR P220101664 A ARP220101664 A AR P220101664A AR 126238 A1 AR126238 A1 AR 126238A1
- Authority
- AR
- Argentina
- Prior art keywords
- formula
- enantiomers
- compounds
- salts
- relates
- Prior art date
Links
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 title 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 230000035772 mutation Effects 0.000 title 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 4
- 150000003839 salts Chemical class 0.000 abstract 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 2
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 101100439664 Arabidopsis thaliana CHR8 gene Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000010261 cell growth Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Esta invención se relaciona con compuestos de fórmula (1) y enantiómeros de estos, y sales aceptables desde el punto de vista farmacéutico de la fórmula (1) y dichos enantiómeros, en donde A se selecciona de carbono y nitrógeno, en donde R³ se puede unir a A cuando es carbono; L¹ se selecciona del grupo que consiste en un enlace, CHR⁸, O, NR⁸ y S; L² se selecciona de NH y O; y R¹, R², R³, R⁴ y R⁸ son como se definen en la presente para dicha fórmula. La invención también se relaciona con compuestos de fórmula (3) y enantiómeros de estos, y sales aceptables desde el punto de vista farmacéutico de la fórmula (1) y dichos enantiómeros, en donde R², R³, R⁵, y n son como se definen en la presente para dicha fórmula. La invención se relaciona además con composiciones farmacéuticas que comprenden tales compuestos y sales, y métodos y usos de tales compuestos, sales y composiciones para el tratamiento del crecimiento celular anormal, que incluye cáncer, en un sujeto que lo necesite.This invention relates to compounds of formula (1) and enantiomers thereof, and pharmaceutically acceptable salts of formula (1) and said enantiomers, wherein A is selected from carbon and nitrogen, wherein R³ can be join to A when it is carbon; L¹ is selected from the group consisting of a bond, CHR⁸, O, NR⁸ and S; L² is selected from NH and O; and R¹, R², R³, R⁴ and R⁸ are as defined herein for said formula. The invention also relates to compounds of formula (3) and enantiomers thereof, and pharmaceutically acceptable salts of formula (1) and said enantiomers, wherein R², R³, R⁵, and n are as defined in the present for said formula. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and methods and uses of such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject in need thereof.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063350495P | 2020-06-09 | 2020-06-09 | |
| US202063294590P | 2020-12-29 | 2020-12-29 | |
| US202163215435P | 2021-06-26 | 2021-06-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR126238A1 true AR126238A1 (en) | 2023-10-04 |
Family
ID=88679247
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220101664A AR126238A1 (en) | 2020-06-09 | 2022-06-24 | HER2 MUTATION INHIBITORS |
Country Status (1)
| Country | Link |
|---|---|
| AR (1) | AR126238A1 (en) |
-
2022
- 2022-06-24 AR ARP220101664A patent/AR126238A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY38553A (en) | CDK2 INHIBITORS | |
| PE20230249A1 (en) | BICYCLIC HETEROARYL COMPOUNDS AND THEIR USES | |
| CL2019000368A1 (en) | CDK2 / 4/6 inhibitors. | |
| ECSP20067394A (en) | CYCLINE-DEPENDENT KINASE INHIBITORS | |
| PH12020551717A1 (en) | Dual atm and dna-pk inhibitors for use in anti-tumor therapy | |
| CY1124239T1 (en) | AMINO-TRIAZOLOPYRIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER | |
| CO2022016377A2 (en) | Fused tricyclic kras inhibitors | |
| CO2022008997A2 (en) | Substituted tricyclic compounds | |
| CY1124680T1 (en) | 8-[6-[3-(AMINO)PROPOXY]-3-PYRIDYL]-1-ISOPROPYL-IMIDAZO[4,5-C]QUINOLINE-2-ONE DERIVATIVES AS SELECTIVE Ataxia Mutated Telangiectasia (ATM) KINASE REGULATORS FOR THERAPEUTIC TREATMENT OF CANCER | |
| AR078157A1 (en) | DERIVATIVES OF PIRAZOL- [4,5-D] PIRROLO [2,3-B] PYRIDINE INHIBITORS OF JAK 2 THYROSINQUINASES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEMSELVES AND USE OF THE SAME IN THE TREATMENT OF CANCER | |
| CO2021006114A2 (en) | 2,3-dihydro-1h-pyrrolo [3,4-c] pyridin-1-one derivatives as hpk1 inhibitors for the treatment of cancer | |
| PE20142339A1 (en) | MACROCYCLICAL DERIVATIVES FOR THE TREATMENT OF DISEASES | |
| DOP2023000281A (en) | HER2 MUTATION INHIBITORS | |
| PE20141351A1 (en) | TRIAZOLOPYRIDINES | |
| MX2020010942A (en) | Dual atm and dna-pk inhibitors for use in anti-tumor therapy. | |
| EA202190323A1 (en) | IMIDAZO [1,2-b] PYRIDAZINES AS TRK INHIBITORS | |
| NZ761680A (en) | Imidazo[1,5-a]pyrazine derivatives as pi3kdelta inhibitors | |
| EA201992090A1 (en) | Deuterated Imidazo [4,5-c] Quinolin-2-One Compounds and Their Use in Cancer Treatment | |
| PE20181447A1 (en) | DERIVATIVES OF CYCLIC ETHER OF PYRAZOLO [1,5-A] PYRIMIDIN-3-CARBOXIAMIDE | |
| MX2018010177A (en) | 6,7-dihydro-5h-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds. | |
| AR126238A1 (en) | HER2 MUTATION INHIBITORS | |
| EA202190322A1 (en) | IMIDAZO [1,2-b] PYRIDAZINE DERIVATIVES AS TRK INHIBITORS | |
| UY28647A1 (en) | AMIDA COMPOUNDS OF ACID 3-AMINO-TIENO (2,3-B) PIRIDIN-2-CARBOXYL REPLACED AND PROCEDURES FOR THEIR PREPARATION AND ITS USES | |
| MX2022001158A (en) | Dual atm and dna-pk inhibitors for use in anti-tumor therapy. | |
| AR122805A1 (en) | HER2 MUTATION INHIBITORS |